[Skip to Content]
[Skip to Content Landing]
December 5, 1980

The Solitary Thyroid Nodule

Author Affiliations

Roswell Park Memorial Institute Department of Health State of New York Buffalo

JAMA. 1980;244(22):2519. doi:10.1001/jama.1980.03310220021009

To the Editor.—  We share the concern and opinion expressed by Blum and Rothschild (1980;243:242) in their article on suppressive therapy for the thyroid nodule. We have previously reported that clinical differentiation of thyroid cancer from benign goiter is satisfactory (1962;181:179). In a double-blind study in which placebo and triiodothyronine (T3) were compared, we have shown that the regression of goiter could be achieved by T3 at a significantly higher rate than the spontaneous regression by placebo (46% vs 9%, P<.001) (1963;185:29).In another randomized doubleblind study, we have also demonstrated that both T3 and thyroxine (T4) were effective in shrinking goiters.1 However, we found that T3 achieves significantly better results than T4 (73% vs 49%, P<.025) and that a modest dose of thyroactive substances (50 μg per day for T3 and 0.2 mg per day for T4) is